Prolongation and enhancement of the anti-apoptotic effects of PTD-Hsp27 fusion proteins using an injectable thermo-reversible gel in a rat myocardial infarction model

Journal of Controlled Release

Volumn 144, Issue 2, 2010, Pages 181-189

  Won, Young Wook ^a   Kim, Jang Kyung ^a   Cha, Min Ji ^b   Hwang, Ki Chul ^b   Choi, Donghoon ^b   Kim, Yong Hee ^a  

^a Hanyang University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Anti apoptosis; Heat shock protein 27 protein transduction domain fusion protein; Ischemia reperfusion; Myocardial infarction; Thermo reversible gel

Indexed keywords

ANTI-APOPTOSIS; FUSION PROTEINS; HEAT SHOCK PROTEIN; ISCHEMIA REPERFUSION; MYOCARDIAL INFARCTION; PROTEIN TRANSDUCTION DOMAINS; THERMOREVERSIBLE GELS;

BACTERIOPHAGES; CARDIOLOGY; CELL DEATH; GELS; HEART; RADIOACTIVITY;

PROTEINS;

HYBRID PROTEIN; PROTEIN TRANSDUCTION DOMAIN HEAT SHOCK PROTEIN 27 FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RELEASE; GEL; GENETIC TRANSDUCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEAT SENSITIVITY; IN VIVO STUDY; MALE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; RAT;

ANIMALS; APOPTOSIS; CELL DEATH; GELS; HALF-LIFE; HSP27 HEAT-SHOCK PROTEINS; INJECTIONS; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; PROTEIN STRUCTURE, TERTIARY; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS;

EID: 77952673226     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.02.014     Document Type: Article

References (22)

1. Choi D., Hwang K.C., Lee K.Y., Kim Y.H. Ischemic heart diseases: current treatments and future. J. Control. Release 2009, 140:194-202.
2. Holmes D.R., Leon M.B., Moses J.W., Popma J.J., Cutlip D., Fitzgerald P.J., Brown C., Fischell T., Wong S.C., Midei M., Snead D., Kuntz R.E. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004, 109:634-640.
3. Lee J., Tan C.Y., Lee S.K., Kim Y.H., Lee K.Y. Controlled delivery of heat shock protein using an injectable microsphere/thermo-reversible gel combination system for the treatment of myocardial infarction. J. Control. Release 2009, 137:196-202.
4. Kim Y.J., Choi S., Koh J.J., Lee M., Ko K.S., Kim S.W. Controlled release of insulin from injectable biodegradable triblock copolymer. Pharm. Res. 2001, 18:548-550.
5. Won Y.W., Kim Y.H. Recombinant human gelatin nanoparticles as a protein drug carrier. J. Control. Release 2008, 127:154-161.
6. Jin K.M., Kim Y.H. Injectable, thermo-reversible and complex coacervate combination gels for protein drug delivery. J. Control. Release 2008, 127:249-256.
7. Latchman D.S. Heat shock proteins and cardiac protection. Cardiovasc. Res. 2001, 51:637-646.
8. Joyeux-Faure M., Arnaud C., Godin-Ribuot D., Ribuot C. Heat stress preconditioning and delayed myocardial protection: what is new?. Cardiovasc. Res. 2003, 60:469-477.
9. Tan C.Y., Ban H., Kim Y.H., Lee S.K. The heat shock protein 27 (Hsp27) operates predominantly by blocking the mitochondrial-independent/extrinsic pathway of cellular apoptosis. Mol. Cells 2009, 27:533-538.
10. Asoh S., Ohta S. PTD-mediated delivery of anti-cell death proteins/peptides and therapeutic enzymes. Adv. Drug Deliv. Rev. 2007, 60:499-516.
11. Wender P.A., Mitchell D.J., Pattabiraman K., Pelkey E.T., Steinman L., Rothbard J.B. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:13003-13008.
12. Jo S., Kim J., Kim S.W. Reverse thermal gelation of aliphatically modified biodegradable triblock copolymers. Macromol. Biosci. 2006, 6:923-928.
13. Lee K.Y., Yuk S.H. Polymeric protein delivery systems. Prog. Polym. Sci. 2007, 32:669-697.
14. Klouda L., Mikos A.G. Thermoresponsive thermo-reversible gels in biomedical applications. Eur. J. Pharm. Biopharm. 2008, 68:34-45.
15. Li L., Thangamathesvaran P.M., Yue C.Y., Tam K.C., Hu X., Lam Y.C. Gel network structure of methylcellulose in water. Langmuir 2001, 17:8062-8068.
16. Chang W., Song B.W., Lim S., Song H., Shim C.Y., Cha M.J., Ahn D.H., Jung Y.G., Lee D.H., Chung J.H., Choi K.D., Lee S.K., Chung N., Lee S.K., Jang Y., Hwang K.C. Mesenchymal stem cells pretreated with delivered Hph-1-Hsp70 protein are protected from hypoxia-mediated cell death and rescue heart functions from myocardial injury. Stem Cells 2009, 27:2283-2292.
17. Jeong B., Kim S.W., Bae Y.H. Thermosensitive sol-gel reversible thermo-reversible gels. Adv. Drug Deliv. Rev. 2002, 54:37-51.
18. Morita T., Horikiri Y., Suzuki T., Yoshino H. Applicability of various amphiphilic polymers to the modification of protein release kinetics from biodegradable reservoir-type microspheres. Eur. J. Pharm. Biopharm. 2001, 51:45-53.
19. Jiang G., Woo B.H., Kang F., Singh J., DeLuca P.P. Assessment of protein release kinetics, stability and protein polymer interaction of lysozyme encapsulated poly(,-lactide-co-glycolide) microspheres. J. Control. Release 2002, 79:137-145.
20. Talasaz A.H.H., Ghahremankhani A.A., Moghadam S.H., Malekshahi M.R., Atyabi F., Dinarvand R. In situ gel forming systems of poloxamer 407 and hydroxypropyl cellulose or hydroxypropyl methyl cellulose mixtures for controlled delivery of vancomycin. J. Appl. Polym. Sci. 2008, 109:2369-2374.
21. Benn S.C., Woolf C.J. Adult neuron survival strategies-slamming on the brakes. Nat. Rev., Neurosci. 2004, 5:686-700.
22. Yockman J.W., Choi D., Whitten M.G., Chang C.W., Kastenmeier A., Erickson H., Albanil A., Lee M., Kim S.W., Bull D.A. Polymeric gene delivery of ischemia-inducible VEGF significantly attenuates infarct size and apoptosis following myocardial infarct. Gene Ther. 2008, 16:127-135.